ZOSTER

(SHINGLES-ZOSTAVAX) VACCINE

VACCINE USAGE: ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

LIMITATIONS OF USE OF ZOSTAVAX:

  • ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia (PHN).
  • ZOSTAVAX is not indicated for prevention of primary varicella infection (Chickenpox).

VACCINE DOSAGE: single 0.65 mL subcutaneous injection.

VACCINE INGEDIENTS: sucrose, hydrolyzed porcine gelatin, monosodium L-glutamate, sodium phosphate dibasic, potassium phosphate monobasic, neomycin, potassium chloride, residual components of MRC-5 cells including DNA and protein, bovine calf serum.

LIVE VIRUS VACCINE THAT HAS THE POTENTIAL TO SHED

ADVERSE VACCINE REACTIONS: injection pain/ swelling, erythema, pruritus, congestive heart failure, deaths caused by cardiovascular disease, nausea, herpes zoster (vaccine strain), rash, arthralgia, myalgia, respiratory infection, fever, rhinitis, skin disorder, diarrhea.